AstraZeneca Wins Two US Drug Approvals
The approvals cover expanded Imfinzi use for bladder cancer and a first-of-its-kind therapy for a rare muscle-weakening disorder.
AstraZeneca LSE:AZN said on Monday it has won two US drug approvals, an expanded bladder cancer use for its immunotherapy Imfinzi and a first-of-its-kind therapy for a rare muscle-weakening disorder.